BOCA RATON, FL--(Marketwired - December 09, 2015) - Dawson James Securities, Inc. today launched coverage of Comparative Biology and Veterinary Biotech with a comprehensive report written by Sherry Grisewood, Managing Partner, Life Science Research.

"We are pleased to initiate research in an emerging sector where we believe investors may find potentially unique and undiscovered opportunities," said Robert D. Keyser, Jr., Dawson James' CEO.

"We believe there are several factors at play driving the emergence of a new era in veterinary medicine which could ignite a vibrant investment thesis," said Grisewood. Grisewood also theorizes that "the merging of vet and human therapeutics has been spurred by advances in veterinary science in areas including gene therapy, regenerative medicine and imaging that are further developed or are already commercialized ahead of the human counterparts."

The Dawson James research publication highlights both public and private companies within the sector alongside of case studies, regulatory issues, challenges and accomplishments.

For a copy of the report, please contact

About Dawson James Securities

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, California, Maryland and New Jersey.

About Sherry Grisewood, Managing Partner, Life Sciences Research

Sherry has over 20 years of experience as a research professional acting in a wide variety of equity investment and corporate-directed research activities, primarily for early stage life science and related technology companies. Sherry has developed particular focus in areas of intersecting technologies such as regenerative medicine, nucleic acid based technologies, immunotherapy and therapeutic medical devices currently under development by US and ex-US life science companies.

Sherry holds a Bachelor of Science degree with Highest Honors from Ramapo College of New Jersey and the Chartered Financial Analyst designation. Sherry is a member of the CFA Institute, NY Society of Security Analysts, and an individual member of the European Federation of Biotechnology, the Tissue Engineering and Regenerative Medicine Society International (TERMIS), the Society of Biomaterials and the American Society of Gene and Cell Therapy.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities mentioned within the report, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.


Contact Information:

For more information, please contact:
Elise Stern
Managing Director, Corporate Finance